Bristol Myers Squibb Reports Narrower Q1 Loss, Beats Revenue Expectations

Despite a challenging quarter with multi-billion dollar acquisitions, Bristol Myers Squibb's sales growth was driven by strong performances from Eliquis and new drugs.